Clinical Trials in Baltimore

Showing 961-980 of 11,213 trials

Evaluating the Infectivity, Safety and Immunogenicity of Respiratory Syncytial Virus Vaccines, RSV 6120/∆NS1 and RSV 6120/F1/G2/∆NS1, in RSV-Seropositive Children and RSV-Seronegative Infants and Children

NCT03596801

The purpose of this study is to evaluate the infectivity, safety, and immunogenicity of a single dose of recombinant, live-attenuated respiratory syncytial virus (RSV) vaccines (RSV 6120/∆NS1 or RSV 6120/F1/G2/∆NS1) in RSV-seropositive children 12 to 59 months of age and RSV-seronegative infants and children 6 to 24 months of age.

RSV Infection

National Institute of Allergy and Infectious Diseases (NIAID)60 participantsStarted Jun 2018

Baltimore, Maryland, United States

COMPLETEDPHASE3< 1 mile

A Study to Test if Fremanezumab is Effective in Preventing Migraine in Children and Adolescents

NCT04530110

The primary objective of the study is to evaluate the long-term safety and tolerability of subcutaneous fremanezumab in the preventive treatment of migraine in pediatric participants 6 to 17 years of age (inclusive at enrollment in the pivotal study). Secondary objectives are to evaluate the efficacy of subcutaneous fremanezumab in pediatric participants with migraine and to evaluate the immunogenicity of fremanezumab and the impact of ADAs on clinical outcomes in pediatric participants exposed to fremanezumab. The total duration of the study is planned to be up to 84 months.

Migraine

Teva Branded Pharmaceutical Products R&D LLC506 participantsStarted Sep 2020

Aurora, Colorado, United States • Colorado Springs, Colorado, United States • Jacksonville, Florida, United States +67 more locations

Evaluating the Infectivity, Safety and Immunogenicity of Respiratory Syncytial Virus Vaccines, RSV 6120/∆NS1 and RSV 6120/F1/G2/∆NS1, in RSV-Seropositive Children and RSV-Seronegative Infants and Children

A Study to Test if Fremanezumab is Effective in Preventing Migraine in Children and Adolescents

Find Trials by Condition in Baltimore

A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease

A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

Adult Congenital Heart Disease International EValuation of the Effectiveness of SGLT2i Registry

VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2)

Safety and Efficacy of the VERTICA® RF Device for the Treatment of ED

Eliminating Monitor Overuse Trial (EMO Trial)

A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors

Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer

Observational Study of LUMRYZ in Narcolepsy

Safety, Tolerability, PK, and PD Study of PGN-EDODM1 in Participants With Myotonic Dystrophy Type 1

Safety and Efficacy of FT218 in Idiopathic Hypersomnia (REVITALYZ)

A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy and Who Are Naïve to Biologic Therapy

A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Participants With High-risk Muscle-invasive Bladder Cancer (MIBC) Who Are ctDNA Positive Following Cystectomy

SPI-62 as a Treatment for Hypercortisolism Related to a Benign Adrenal Tumor

Specialized Pro-resolving Lipid Mediators and Treatment Resistant Depression

Study to Assess Safety, Efficacy and Persistence of ACE1831, in Subjects With IgG4-Related Disease

Post Market Clinical Follow-up (PMCF) Study of the A.L.P.S. Proximal Humerus Plating System

A Safety and Efficacy Extension Study of Pertuzumab in Patients With Solid Tumors Previously Enrolled in a Hoffmann-La Roche-Sponsored Pertuzumab Clinical Trial